Diagenode

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia


Dorien Pastoors et al.

Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in an aggressive subtype of acute myeloid leukemia (AML). Direct depletion of MECOM using an endogenous auxin-inducible degron immediately upregulates expression of myeloid differentiation factor CEBPA. MECOM depletion is also accompanied by a severe loss of stem cells and gain of differentiation. MECOM exerts its inhibitory effect by binding to the +42kb CEBPA enhancer, a gene essential for neutrophil development. This is partially dependent on the interaction between MECOM and its co-repressor CTBP2. We demonstrate that CEBPA overexpression can bypass the MECOM-mediated block of differentiation. In addition, AML patients with MECOM overexpression through enhancer hijacking show significantly reduced CEBPA. Our study directly connects two main players of myeloid transformation MECOM and CEBPA, and it provides insight into the mechanism by which MECOM maintains the stem cell state in a unique subtype of AML by inactivating CEBPA.

Tags
Antibody
Microplex Library Preparation kit

Share this article

Published
January, 2025

Source

Products used in this publication

  • chip kit icon
    C05010001
    MicroPlex Library Preparation Kit v3 /48 rxns
  • cut and tag antibody icon
    C15410196
    H3K27ac Antibody
  • ChIP-seq Grade
    C15200211
    p300 Antibody
  • cut and tag antibody icon
    C15410193
    H3K9me3 Antibody

Events

 See all events

 


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy